Supernus Pharmaceuticals Inc (SUPN)

Net profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	141	25,622	43,347	52,043	60,711	37,672	57,485	73,346	53,424	81,750	100,185	111,126	126,950	129,311	118,174	116,234	113,056	105,820	104,971	102,981
Revenue (ttm)	US$ in thousands	605,106	619,414	641,163	674,751	673,056	651,277	618,187	585,808	560,079	545,016	551,524	536,576	506,717	465,383	418,476	402,257	392,755	408,243	409,099	403,942
Net profit margin		0.02%	4.14%	6.76%	7.71%	9.02%	5.78%	9.30%	12.52%	9.54%	15.00%	18.17%	20.71%	25.05%	27.79%	28.24%	28.90%	28.79%	25.92%	25.66%	25.49%

December 31, 2023 calculation

Net profit margin = Net income (ttm) ÷ Revenue (ttm)
= $141K ÷ $605,106K
= 0.02%

Supernus Pharmaceuticals Inc's net profit margin has exhibited some fluctuation over the past eight quarters. The trend demonstrates a decline from 9.10% in Q4 2022 to 0.22% in Q4 2023, which is a notable decrease in profitability. This may suggest challenges in managing expenses or generating revenue efficiently during the most recent quarter. The average net profit margin over this period is 6.68%, indicating that the company has generally maintained a moderate level of profitability. However, the decreasing trend in recent quarters warrants further investigation to assess the company's operational efficiency and financial health.